This study demonstrated that a linezolid PA program did not appear to be associated with a negative impact on medical outcomes and was associated with lower costs.
R. Scott McClelland, PharmD
Advertisement
Articles by R. Scott McClelland, PharmD
Advertisement
Latest Updated Articles
- A Linezolid Prior Authorization Program: Clinical and Economic Outcomes
Published: April 16th 2014 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer
2
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
3
Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer
4
Under Pressure: A Brief Overview of the Updated Hypertension Guidelines
5
